Themis Medicare share news, announcements and annual reports
NSE: THEMISMEDBSE: 530199Pharmaceuticals & BiotechnologySmall Cap
Themis Medicare Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1995 on BSE, Apr 2007 on NSE
Last close ₹94.83down ₹2.69 (2.76%)BSE ₹95.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹97.52.
30 Oct: open ₹97.39, high ₹99.58, low ₹94.02
52-week range of traded prices to 30 Oct 2026
₹64.95Low, 30 Mar 2026₹140.60High, 7 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹873 Cr1,570th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 21.85
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹92 crore of one-off items, the largest of them in the quarter to Jun 2026.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.19
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.53%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.0%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹92 crore of one-off items, the largest of them in the quarter to Jun 2026.
- −13.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −10.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.25
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 60,90035.0% delivered
Themis Medicare board and management
36 filed, newest first.
Aug 2026
13 Aug · Management
13 Aug · Management
13 Aug · Management
13 Aug · Management
Feb 2026
Nov 2025
10 Nov · Management
Aug 2024
Jul 2024
Jun 2024
6 Jun · Management
Sep 2023
May 2023
Oct 2022
Sep 2022
Mar 2022
Sep 2021
Mar 2019
27 Mar · Management
27 Mar · Management
Mar 2018
27 Mar · Management
Dec 2016
23 Dec · Management
Jun 2016
May 2015
Nov 2011
4 Nov · Management
At the meeting of the Board of Directors of the Company held on November 04, 2011 Mr. Erik Bogsch, Representative of Foreign Collaborator resigned as Director and his resignation was approved by the Board of Directors.
May 2011
3 May · Management
Mrs. Jayshree D. Patel, Whole Time Director resigned from the Board from the conclusion of the meeting of the Board of Directors of the Company held on May 03, 2011.
Jul 2010
31 Jul · Management
Shri H.N. Sinor stepped down as Chairman of the Audit Committee of the Company. However, the Audit Committee/Board were pleased to appoint Mr. Humayun Dhanrajgir is Chairman - Audit Committee, and Mr. H.N. Sinor will continue as Member of the Audit Committee.
Apr 2010
27 Apr · Management
Remuneration Committee and the Board of Directors of the Company at its Meeting held on April 27, 2010 has recommended reappointment of Dr. Dinesh S. Patel and Mrs. Jayshree D. Patel for a term of five years as Managing Director & CEO and Whole Time Director respectively, as well as Dr. Sachin D. Patel is re-designated as Deputy Managing Director, on revised remuneration terms w.e.f. June 29, 2010.
Jan 2009
30 Jan · Management
Board of Directors at their meeting held on January 30, 2009 appointed Shri Rajneesh Anand, as an Additional Director.
Jul 2008
31 Jul · Management
Board of Directors of the Company at its meeting held on July 31, 2008 the board considered and approved the Resignation of Shri Shantibhai D. Patel, as Chairman of the Company. However, the Board was pleased to appoint him as Chairman- Emeritus. The Board also appointed Shri. Hoshang N. Sinor, an Independent & Professional Director as the Chairman of the Company in place of Shri S. D.Patel.
Jul 2007
18 Jul · Management
At the Board Meeting held on July 18, 2007, Dr.Dinesh S. Patel, Mrs.Jayshree D. Patel and Dr.Sachin D. Patel were reappointed as Directors for a period of three years on revised remuneration. The aforesaid appointment and revised remuneration are subject to the provisions of the Companies Act, 1956.
Apr 2007
30 Apr · Management
The Board Meeting of the Company was held on 27th April, 2007 to discuss the regular business affairs of the Company. Further, in the said meeting Mr.Rajneesh Anand was also appointed as Alternate Director of the Company pursuant to Section 313 of the Companies Act, 1956